Zacks Investment Research Lowers Xenetic Biosciences, Inc. (XBIO) to Hold
Xenetic Biosciences, Inc. (NASDAQ:XBIO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “
Xenetic Biosciences (XBIO) traded up 3.27% during mid-day trading on Wednesday, hitting $2.21. 15,785 shares of the stock traded hands. Xenetic Biosciences has a 52-week low of $1.75 and a 52-week high of $5.90. The firm’s market cap is $19.26 million. The firm’s 50-day moving average is $2.60 and its 200 day moving average is $2.59.
Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.13). Equities analysts predict that Xenetic Biosciences will post ($0.89) EPS for the current fiscal year.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.